Ads
related to: complement inhibitor drugsvyvgarthcp.com has been visited by 10K+ users in the past month
goodrx.com has been visited by 100K+ users in the past month
Search results
Results from the WOW.Com Content Network
It is a humanized monoclonal antibody functioning as a terminal complement inhibitor. [13] It binds to the complement C5 protein and inhibits activation of the complement system, a part of the body's immune system. [16]
C1-inhibitor (C1-inh, C1 esterase inhibitor) is a protease inhibitor belonging to the serpin superfamily. [5] Its main function is the inhibition of the complement system to prevent spontaneous activation but also as the major regulator of the contact system.
Pegcetacoplan acts as a complement inhibitor, specifically targeting complement protein C3, which plays a crucial role in the pathogenesis of paroxysmal nocturnal hemoglobinuria (PNH). In individuals with PNH, there is a heightened and uninhibited complement activity, which may lead to intravascular (inside blood vessels) or extravascular ...
Ravulizumab, sold under the brand name Ultomiris, is a humanized monoclonal antibody complement inhibitor medication designed for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome. It is designed to bind to and prevent the activation of Complement component 5 (C5). [8] [7]
It is a complement factor B inhibitor that was developed by Novartis. [4] It is taken by mouth. [4] Iptacopan was approved by the US Food and Drug Administration (FDA) for the treatment of adults with paroxysmal nocturnal hemoglobinuria in December 2023. [6] [7] The FDA considers it to be a first-in-class medication. [8]
It is a complement component 5 (C5) inhibitor. [1] [4] Crovalimab was approved for use in China in February 2024, [5] in Japan in April 2024, [6] in the United States in June 2024, [7] [8] and in the European Union in August 2024. [2] [3] It was developed and is marketed by Roche/Genentech. [citation needed]
Zilucoplan, sold under the brand name Zilbrysq, is a medication used for the treatment of generalized myasthenia gravis. [6] [9] [10] It is a complement inhibitor that is injected subcutaneously (under the skin).
Danicopan, sold under the brand name Voydeya, is a medication used for the treatment of paroxysmal nocturnal hemoglobinuria. [6] [7] It is a complement inhibitor which reversibly binds to factor D to prevent alternative pathway-mediated hemolysis and deposition of complement C3 proteins on red blood cells.
Ads
related to: complement inhibitor drugsvyvgarthcp.com has been visited by 10K+ users in the past month
goodrx.com has been visited by 100K+ users in the past month